BioSpace

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma's psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events.

By BioSpace

1 min read
Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights